From Data to Decisions: Rethinking the Role of Biostatistics in Clinical Trials

In this episode, Greg sits down with Rebecca Asher to unpack how biostatistics has evolved into a critical driver of clinical trial success. What was once a back-end function is now shaping studies from the very beginning, influencing everything from endpoints to overall design. They explore how modern trials, decentralized data collection, and new regulatory expectations are changing the way sponsors need to think about data. Rebecca shares practical insight on avoiding common pitfalls, especially around missing data and overcomplicating analysis. If you want to understand how to design trials that actually deliver meaningful results, this conversation is well worth your time.“The Bench 2 Breakthrough Podcast” is the official podcast of Accelagen, created to share real-world insights from the clinical and regulatory front lines of biotech and pharmaceutical development. Hosted by Accelagen founder and CEO Greg Plunkett alongside co-host Rosa Plunkett, the podcast explores global, regional, and local industry news, emerging challenges, and new opportunities shaping the CRO landscape. Each episode blends practical experience with thoughtful discussion, featuring expert guests and perspectives that help sponsors navigate development pathways more efficiently. From early discovery to clinical execution, Bench 2 Breakthrough is about turning scientific progress into meaningful outcomes for patients.Accelagen is a Melbourne-based, award-winning Contract Research Organisation (CRO) specializing in end-to-end clinical trials, regulatory affairs, and biometrics for pharmaceutical and biotechnology companies. Founded in 2010, it supports Phase I-IV trials and offers strategic guidance for drug and medical device development. We believe the future of human health needs a fresh, future-focused approach. We challenge existing conventions to deliver commercially savvy and patient-centric outcomes for leading biopharmaceutical and medical device companies in the fast-growing global trials market across Australia, North America, Asia Pacific, and Europe.